• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

    FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

  2. FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

    FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

  3. Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

    Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

  4. Top Holdings of Four All-Weather Ultimate Stock-Pickers

    While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.

  5. These Foreign Stocks Are Medalist Fund Favorites

    More than a dozen analyst-approved foreign large-cap funds own these names.

  6. Top 10 Holdings of Our Best-Performing Ultimate Stock-Pickers

    While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.

  7. Allergan Defends Its Territory Against Increased Competition

    Brand recognition and product innovation keep the firm's moat wide.

  8. The Case for a Concentrated 1-Star Fund

    This fund's comeback from the financial crisis has been balky, but it still has promise.

  9. Digging Moats in China

    Foreign firms that have established competitive advantages in China are well-positioned to profit from consumption growth.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.